Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
melatonin + dehydroepiandrosterone
- Development stage
- Unknown
- Lead developer
- Xiangya Hospital, Central South University
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
This combination therapy involves the co-administration of melatonin, a potent antioxidant and circadian regulator, and dehydroepiandrosterone (DHEA), an endogenous steroid precursor. It is primarily investigated for improving clinical outcomes in women with diminished ovarian reserve (DOR) or polycystic ovary syndrome (PCOS) undergoing assisted reproductive technologies (ART). DHEA is thought to enhance the follicular microenvironment and increase the number of recruitable follicles by acting as a precursor for follicular androgens, which promote early-stage follicular growth. Melatonin acts as an antioxidant within the follicular fluid, protecting oocytes from oxidative stress and potentially improving oocyte maturation and embryo quality. Research led by institutions like Xiangya First Hospital of Central South University has explored this combination to optimize IVF/ICSI outcomes, focusing on its ability to improve the number of retrieved oocytes and pregnancy rates.
- Other names
- DHEA + melatoninmelatonin and DHEA
02
Targets
MTNR1A (MT1)AR (Adrenergic receptors)
Beyond the preview
Go deeper on melatonin + dehydroepiandrosterone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on melatonin + dehydroepiandrosterone.